Kite Pharma (KITE) Receives Analyst Rating

Kite Pharma (KITE) : The consensus on Kite Pharma (KITE) based on 9 analyst recommendation on the company stock is 1.33, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Kite Pharma (KITE) : The most positive equity analysts on Kite Pharma (KITE) expects the shares to touch $80, whereas, the least positive believes that the stock will trade at $60 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $71.5 with an expected fluctuation of $7.52 from the mean.


Also, BTIG Research initiates coverage on Kite Pharma (NASDAQ:KITE) . Analysts at the BTIG Research have a current rating of Neutral on the shares. The rating by the firm was issued on August 30, 2016.

Kite Pharma (NASDAQ:KITE): After opening at $55.14, the stock dipped to an intraday low of $53.79 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $55.66 and the buying power remained strong till the end. The stock closed at $55.37 for the day, a gain of 1.11% for the day session. The total traded volume was 707,286. The stocks close on the previous trading day was $54.76.

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.